Femasys Inc. Common Stock (FEMY) — 分析摘要
Femasys Inc. Common Stock(FEMY)的市值为9.24百万美元,最近一年的营收同比增长了+40.8%。净利润率为-812.3%。当前市盈率为-0.8倍。
核心要点
- 营收同比变化+40.8%
- 净利润率-812.3%
- 市盈率-0.8倍
与SURGICAL & MEDICAL INSTRUMENTS & APPARATUS板块的其他公司相比,FEMY的营收增长为+40.8%,市盈率为-0.8倍。
Femasys Inc. Common Stock (FEMY)
更新 — ET · 来源 POLYGON
红旗与风险提示高风险信号
存在多项实质性红旗,在依赖任何估值输出前应先重点核查这些风险。
利息保障倍数为 -10.2x — 盈利不足以覆盖利息支出
营业利润率为 -687.9% — 严重经营亏损
净利率为 -500.0% — 亏损超过收入(可能含一次性费用)
最新报表显示自由现金流为负。
Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. Its product portfolio includes FemaSeed Intratubal Insemination, an infertility treatment; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemBloc, a clinical product candidate being developed as a permanent birth control; FemCerv, a tissue sampler for cervical cancer diagnosis; and FemCath and FemChec. Geographically, it derives key revenue from the United States and rest from international markets.
行业
SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
员工人数
54
总部
SUWANEE, GA
Exchange
XNAS
基于 4 年财务数据的系统性竞争优势评估
此评估基于历史财务数据的量化分析,不构成投资建议。护城河评级可能随行业和竞争环境变化。
首版展示近期 SEC Forms 3、4、5 备案活动。尚未解析单笔买入/卖出交易。
资本结构
现金流
免责声明:本站内容不构成投资建议。数据来源于SEC EDGAR和Polygon.io。过往业绩不代表未来表现。投资决策前请自行研究。